Evidence map›Paper›PMID 33608329›Full record

ArticleDiabetes care2021

Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.

Roselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A Fielding, Agampodi Mendis, Sigurd Johnsen, A Margot Umpleby, Melanie Davies and 1 more

Open access · bronzeAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Roselle A HerringCentre for Endocrinology, Diabetes and Research, Royal Surrey County Hospital, Guildford, U.K. roselle.herring@nhs.net.ORCID 0000-0002-8267-6236
Fariba Shojaee-MoradieCentre for Endocrinology, Diabetes and Research, Royal Surrey County Hospital, Guildford, U.K.
Robert GaresseCentre for Endocrinology, Diabetes and Research, Royal Surrey County Hospital, Guildford, U.K.
Mary StevenageCentre for Endocrinology, Diabetes and Research, Royal Surrey County Hospital, Guildford, U.K.
Nicola JacksonDepartment of Nutritional Sciences, University of Surrey, Guildford, U.K.
Barbara A FieldingDepartment of Nutritional Sciences, University of Surrey, Guildford, U.K.
Agampodi MendisDepartment of Nutritional Sciences, University of Surrey, Guildford, U.K.
Sigurd JohnsenDepartment of Nutritional Sciences, University of Surrey, Guildford, U.K.
A Margot UmplebyDepartment of Nutritional Sciences, University of Surrey, Guildford, U.K.
Melanie DaviesDiabetes Research Centre, Department of Health Sciences, University of Leicester, Leicester, U.K.
David L Russell-JonesCentre for Endocrinology, Diabetes and Research, Royal Surrey County Hospital, Guildford, U.K.ORCID 0000-0002-9490-2480
Royal Surrey County Hospital · GBUniversity of Surrey · GBUniversity of Leicester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 1KetosisSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsGlucosidesHumansInsulinBenzhydryl CompoundsdapagliflozinGlucosidesInsulinSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID33608329
OpenAlexW3131384455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.